Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
Date:3/10/2009

SAN CARLOS, Calif., March 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Cowen and Company 29th Annual Healthcare Conference in Boston at the Boston Marriott Copley Plaza on Monday, March 16, 2009 at 2:25 p.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until April 1, 2009.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own potentially high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. For more information on Nektar Therapeutics, please visit http://www.nektar.com.

    Nektar Contacts:

    Jennifer Ruddock
    Nektar Therapeutics
    650-631-4954
    jruddock@nektar.com

    Susan Noonan
    The SAN Group
    212-966-3650
    susan@sanoonan.com


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
2. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
3. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
8. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. West Concludes Agreement with Nektar
11. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to announce that ... County Fair to be held August 5-9 in Marshall. The Ralco Enrichment Center is ... from and how agriculture impacts their daily lives. This unique exhibit also features a ...
(Date:7/30/2015)... TX, USA (PRWEB) , ... July 30, 2015 ... ... and microsystems, has appointed Francois Vieillard as Sales & Marketing Director. , ... positions, Francois Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... field clinical study of its canine osteoarthritis stem cell product, currently under development ... City, KS) and will be marketed in the US by Aratana. This product, ...
(Date:7/30/2015)... customers across the globe, ISN improves the efficiency and effectiveness of contractor management systems. ... and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Headquartered in Dallas, TX , ISN has additional offices in ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3
... Burrill Merchant Banking acted as,exclusive financial advisor to ... with Nycomed.,Under the terms of the agreement, NPS ... Nycomed for the treatment of gastrointestinal disorders., ... the treatment of,short-bowel syndrome (SBS). SBS can result ...
... Advancement; CAMVIA Momentum Building Toward 2009 ... ... VPHM ) today announced Michel de Rosen, ViroPharma,s president and,chief executive ... update during the 26th Annual JPMorgan Healthcare,Conference. As previously announced, this presentation ...
... Jan. 9 Quintiles,Transnational Corp. today announced the ... Operations for the company,s Public Health and,Government Services ... diseases and vaccine product development. He will report ... Officer, and Head,of the Public Health and Government ...
Cached Biology Technology:Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement 2ViroPharma Provides 2008 Outlook 2ViroPharma Provides 2008 Outlook 3ViroPharma Provides 2008 Outlook 4ViroPharma Provides 2008 Outlook 5ViroPharma Provides 2008 Outlook 6Quintiles Names Kelly McKee Executive Director of Operations for Public Health and Government Services Unit 2
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... it has filed provisional patent 62/198989 for ... invention highlights a method to advance crypto-currencies such as ... introducing a common, uniform way to manage all payments.  ...
(Date:7/23/2015)... 23, 2015 Aware, Inc. (NASDAQ: AWRE ), ... financial results for its second quarter ended June 30, 2015.  ... was $4.5 million, a decrease of 33% compared to $6.8 ... the second quarter of 2015 was $0.3 million, or $0.01 ... per diluted share, in the same period a year ago.  ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... 2011) - A new study has found that most patients ... recommended number of samples to diagnose celiac disease. The ... Endoscopy , analyzed a national database of biopsy specimens maintained ... patients had a biopsy of the small intestine, but only ...
... leaves can vary by a factor of 1,000 across plant species, ... new study by an international team of scientists led by UCLA ... In research federally funded by the National Science Foundation, the ... to dry soil because of their distinct vein systems. ...
... The Damon Runyon Cancer Research Foundation, a ... researchers, named 18 new Damon Runyon Fellows at ... recipients of this prestigious, three-year award are outstanding ... in the laboratories of leading senior investigators across ...
Cached Biology News:Low adherence to biopsy guidelines affects celiac disease diagnosis in the United States 2Being small has its advantages, if you are a leaf 2Being small has its advantages, if you are a leaf 3Being small has its advantages, if you are a leaf 4Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 2Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 3Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 4Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 5Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 6
RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
RABBIT ANTI D-TYROSINE CONJUGATE...
UV LAMP 300 NM 8W T5, 1 EA. Category: Nucleid Acid Detection Systems....
Kit for Detection of Mitochondrial Membrane Potential...
Biology Products: